Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
Key Highlights
- ➤ACCEL Phase 3 trial fully enrolled ahead of schedule
- ➤Topline ACCEL data expected in the second half of 2027
- ➤IBSRELA is not approved for chronic idiopathic constipation
- ➤Ardelyx has two U.S.-approved commercial products
Expert Statements
Michael Raab, President and Chief Executive Officer of Ardelyx
“Completing enrollment ahead of schedule in our Phase 3 clinical trial marks an important milestone for the Company”
Michael Raab, President and Chief Executive Officer of Ardelyx
“The interest and pace of enrollment in the trial underscores the enthusiasm on the part of treating physicians for a new option for their patients experiencing the significant burden of CIC.”
Michael Raab, President and Chief Executive Officer of Ardelyx
“We are grateful to the patients, the clinical teams and investigators at our trial sites whose commitment made this milestone possible.”
Michael Raab, President and Chief Executive Officer of Ardelyx
“We look forward to sharing topline results in 2027.”
Rajani Dinavahi, Chief Medical Officer of Ardelyx
“Many CIC patients continue to experience symptoms despite available therapies, indicating the need for additional treatment options that provide sustained, meaningful relief”
Rajani Dinavahi, Chief Medical Officer of Ardelyx
“Evaluating the use of IBSRELA for patients with CIC is an important objective for Ardelyx.”
Rajani Dinavahi, Chief Medical Officer of Ardelyx
“CIC can impose a substantial burden on daily life, particularly after cycling through multiple over the counter and prescription treatments.”
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it has fully enrolled ahead of schedule all patients in the Phase 3 ACCEL clinical trial evaluating the safety and efficacy of IBSRELA(®) (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. Topline data is expected in the second half of 2027.
“Completing enrollment ahead of schedule in our Phase 3 clinical trial marks an important milestone for the Company,” said Michael Raab, President and Chief Executive Officer of Ardelyx. “The interest and pace of enrollment in the trial underscores the enthusiasm on the part of treating physicians for a new option for their patients experiencing the significant burden of CIC. We are grateful to the patients, the clinical teams and investigators at our trial sites whose commitment made this milestone possible. We look forward to sharing topline results in 2027.”
Get started
Create a free account to read the full story.